TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : QIN et al

Serial No.: 09/875,456

Art Unit:

Filed

: June 6, 2001

Examiner:

For

THE HUMAN VOLTAGE GATED SODIUM CHANNEL B1A SUBUNIT

AND METHOD OF USE

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

> February 12, 2002 (Date of Deposit) Myra H. McCormack egistered Representative) (Name of applicant, February 12, 2002 (Date of Signature)

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. **§**1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

∐ In a	ccordance with §1.129(a), this Information
Disclosure Stat	tement is being filed in connection with \square the
first or 🗌 seco	ond After Final Submission, therefore:
	Statement in Accordance with §1.97(e) (attached)
	or
	Please charge Deposit Account No. 10-0750/ /
	the fee of $$180.00$ as set forth in $$1.17(p)$.

In accordance with §1.97(c), this Information

Disclosure Statement is being filed after the period set forth

in §1.97(b) above but before the mailing date of either a Final

Action under §1.113 or a Notice of Allowance under §1.311, or an

action that otherwise closes prosecution and that it is

accompanied by one of:

Statement in Accordance with §1.97(e) (attached);
or Please charge Deposit Account No. 10-0750/ /
the fee of $$180.00$ as set forth in $$1.17(p)$.
☐ In accordance with § 1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in § 1.17(p).
Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO- 1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
There are no listed references which are not in the English language.

The relevance of those listed references which are not in the English language is as follows: Attached are copies of search report(s) from П corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1448/MHM. This form is submitted in triplicate. Respectfully submitted, Myra H. McCormac Reg. No. 36602 Attorney for Applicants Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-6932 DATED: February 12, 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Under the Paperwor Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 4

s are required to respond to a collection of less it displays a valid OMB control number.			MAR
Application Number	09/875,456	S S	ī
Filing Date	June 6, 2001	- !!! -	-J.
First Named Inventor	Qin, et al.	160	4
Group Art Unit	1615	8	弔
Examiner Name		- 22	\dashv
Attorney Docket Number	ORT-1448	8	7

U.S. PATENT DOCUMENTS U.S. Patent Document Examiner Name of Patentee or Applicant Cite Date of Pages, Columns, Lines, Initials Publication of Kind Code² No.1 of Cited Document where relevant Cited Document passages or relevant Number mm-dd-yyyy figures appear (if known)

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Pages, Columns, Name of Patentee or Publication of Lines, where Examine Cit Cited Document relevant passages Applicant of Cited Document T⁶ $Office^{3}$ Number⁴ or relevant mm-dd-yyyy Initial KindCode⁵ No. figures appear

Examine r	7/0	Date	
Signatu re		Considere d	7- 7/- 07
	Tritto) is me		J - J/

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued

code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the

number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if

possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FEB 2 5 2002 DE COMPANY A PRINT 2 TO PRINT 2

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
of 1995, no parents are required to respond to a collection of

erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

FEB 2 S

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 4

-			
	Application Number	09/875,456	
ı	Filing Date	June 6, 2001	
I	First Named	Qin, et al.	=
	Inventor		<u> </u>
1	Group Art Unit	1615	160p/290c
i	Examiner Name		<u> </u>
1	Attorney Docket	`ORT-1448	8
	Number		

		OTHER PRIOR ART - MON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITOL LETTERS), title of the article (when	
Examiner	Cit	appropriate), title of the item (book, magazine, journal, serial, symposium,	T ²
's	e	catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or	
Initials	No.	country where published	
*	1		
0.0	1	BALSER, JEFFREY R, "Structure And Function Of The Cardiac Sodium Channels," Cardiovascular	
	· l	Research (1999) 42:327-338	د ۔۔
	2	CATTERALL, William A., "Cellular And Molecular Biology Of Voltage-Gated Sodium Channels,"	
		Pharmaceutical Rev." (1992) 72 (4) S15-S48	,
	3	CATTERALL, William A., "Structure And Function Of Voltage-Gated Ion Channels", Trends Neurosci (1993)	
		16:500-506	
	-4	CHABAL, Charles, Et Al., "The Effect Of Intravenous Lidocaine, Tocainide, And Mexiletine On	
	•	Spontaneously Active Fibers Originating In Rat Sciatic Neuromas, Pain," (1989) 38:333-338	
	3	CHAPLAN, S.R., et al., "QUANTITATIVE ASSESSMENT OF TACTILE ALLODYNIA IN THE RAT PAW,"	
	-	JOURNAL OF NEUROSCIENCE METHODS (1994) 53:55-63	
	6	D'ANDREA, MICHAEL R., et al. "CHARACTERIZATION OF PROTEASE-ACTIVATED RECEPTOR-2	
9 /		IMMUNOREACTIVITY IN NORMAL HUMAN TISSUES," JOURNAL OF HISTOCHEMISTRY &	
		CYTOCHEMISTRY, (1998) VOL. 46(2): 157-164	1 1
	7	DEVOR, MARSHALL et. al., "NA+ CHANNEL ACCUMULATION ON AXOLEMMA OF AFFERENT	
		ENDINGS IN NERVE END NEUROMAS IN APTERONOTUS," NEUROSCIENCE LETTERS, 102 (1989)	
1		149-154	
	8	DEVOR, MARSHALL, "THE PATHOPHYSIOLOGY OF DAMAGED PERIPHERAL NERVES, IN TEXTBOOK	
	. –	OF PAIN." eds Wall PD, Melzack R., (Churchill Livingstone, Edinburgh) 2nd ED, (1994) pp.79-101	
	9	DEVOR, MARSHALL, et al., "SYSTEMIC LIDOCAINE SILENCES ECTOPIC NEUROMA AND DRG	
	-	DISCHARGE WITHOUT BLOCKING NERVE CONDUCTION, PAIN," (1992) 48:261-268	I
_			
C	10	DIB-HAJJ, et al. "Down-Regulation of Transcripts for Na Channel α-SNS IN SPINAL SENSORY NEURONS	_
		FOLLOWING AXOTOMY," Proc. Natl acad. Sci. (USA) (1996) Vol. 93:14950-14954.	
	11	ECKER, DAVID J., et al., "Increasing Gene Expression In Yeast By Fusion To Ubiquitin," Journal of	
		Biological Chemistry (1989) Vol. 264, 7715-7719	-
	12	ENGLAND JD, et al, "Sodium channels accumulate at the tips of injured axons." Muscle Nerve (1994)	
		17:593-598.	مه
	13	ENGLAND, J.D., et al. "Sodium Channel Accumulation In Humans With Painful Neuromas," American	
Y		Academy of Neurology, (1996) 47:272-276.	
	14	GOULD, HARRY J. III, et al., "Rapid Sodium Channel Augmentation In Response To Inflammation Induced	
		By Complete Freund's Adjuvant," Brain Research (1998) 802:69-74	
5	15	HOROWITZ, et al, "Synthesis And Assembly Of Functional Mammalian Na,K-Atpase In Yeast," Journal of	
		Biological Chemistry (1990) 265:4189-4192	
0.0	16	ISOM, L.L., et al. "Primary Structure And Functional Expression Of The β ₁ Subunit Of The Rat Brain Sodium	
		Channel," Science (1992) Vol. 256:839-842	
	17	ISOM, L.L., et al. "Structure And Function Of The β2 Subunit Of Brain Sodium Channels, A Transmembrane	
		Glycoprotein With A Cam Motif," Cell, (1995) Vol. 83:433-442	[]

Examiner		Date	ר ר	12-9)
Signature	1 John M	Considered	3)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FEB 2 5 2002 His

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of

information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 3 of 4

Toda it dispisação a valida dem concret number.				
09/875,456	I			
June 6, 2001	35			
Qin, et al.				
	න			
1615	-6			
	<u> </u>			
ORT-1448	8			
	09/875,456 June 6, 2001 Qin, et al.			

2	18	ISOM, L.L., et al. "AUXILIARY SUBUITS OF VOLTAGE-GATED ION CHANNELS," Neutron, (1994), Vol 12 1183-1194	
~	19	JACOBSON, et al., "Expression And Secretion Of Biologically Active Echistatin In Saccharomyces Cerevisiae," Gene (1989) 85:5II-516	
1	20	KITTS, PAUL A., et al., "Linearization Of Baculovirus DNA Enhances The Recovery of Recombinant Virus Expression Vectors," Nucleic Acids Research (1990), 5667-5672	_
9	21	MARBAN, et. al., "Structure And Function Of Voltage-Gated Sodium Channels," Journal of Physiology (1998), 647-657	_
~	22	MATZNER et al., "Na+ Conductance And The Threshold For Repetitive Neuronal Firing," Brain Research (1992) 92-98	_
~	23	MATZNER O, et al., "Hyperexcitability at sites of nerve injury depends on voltage-sensitive Na+ channels," J.Neurophysiol (1994) 72:349-359.	_
2	24	MCDONNELL, D. et.al., "RECONSTRUCTION OF THE VITAMIN D-RESPONSIVE OSTEOCALCIN TRANSCRIPTION UNIT IN SACCHAROMYCES CEREVISIAE," Molecular & Cellular Biology, Vol.9 No. 8: 3517-3523 (1989)	-
~	25	NORDIN, et al., "ECTOPIC SENSORY DISCHARGES AND PARESTHESIAE IN PATIENTS WITH DISORDERS OF PERIPHREAL NERVES, DORSAL ROOTS AND DORSAL COLUMNS," Pain 20 (1984), 231-245	_
0	26	OCHOA, et al., "PARAESTHESIAE FROM ECTOPIC IMPULSE GENERATION IN HUMAN SENSORY NERVES," Brain (1980) 103, 835-853	-
2	27	OH, YOUNGSUK, et al., "Na+ Channel β1 SUBUNIT mRNA; DIFFERENTIAL EXPRESSION IN RAT SPINAL SENSORY NEURONS," Molecular Brain Research, 30 (1995) 357-361	·
1	28	OMANA-ZAPATA, IMELDA, et al., "Tetrodotoxin Inhibits Neuropathic Ectopic Activity In Neuromas, Dorsal Root Ganglia And Dorsal Horn Neurons," Pain 72 (1997) 41-49	,
V	29	PORRECA, FRANK, et al., "A Comparison Of The Potential Role Of The Tetrodotoxin-Insensitive Sodium Channels, Pn3/Sns And Nan/Sns2, In Rat Models Of Chronic Pain," Proc. Natl. Acad. Sci., USA, Vol. 96 (1999) 7640-7644	-
2	30	RIEHL-BELLON, NADINE et al., "Purification And Biochemical Characterization Of Recombinant Hirudin Produced By Saccharomyces Cerevisiae," Biochemistry 28 (1989) 2941-2949	1
	31	RINAS, URSULA, et al., "CHARACTERIZATON OF RECOMBINANT FACTOR Xiiia PRODUCED IN SACCHAROMYCES CEREVISIAE," Biotechnology June (1990), 543-546	/
	32	RIZZO, MARCO A., "Successful Treatment Of Painful Traumatic Mononeuropathy With Carbamazepine; Insights Into A Possible Molecular Pain Mechanism," Journal of Neurological Sciences, 152 (1997) 103-106	
~	33	SABIN, E. et al., "High-Level Expression And In Vivo Processing Of Chimeric Ubiquitin Fusion Proteins In Saccharomyces Cerevisiae," Biotechnology (1989) Vol. 7: 705-709	
~	34	SLEEP, D, et al., "The Secretion Of Human Serum Albumin From The Yeast Saccharomyces Cerevisiae Using Five Different Leader Sequences," Biotechnology, (1990) Vol., 8:42-45	
~	35	SUTKOWSKi et al.," β1 Subunits Of Sodium Channels," The Journal of Biological Chemistry 265 (1990)12393-12399	_
	36	TANAKA, M., et al., "Sns Na+ Channel Expression Increases in Dorsal Root Ganglion Neurons In The Carrageenan Inflammatory Pain Model," Molecular Neuroscience, (1998) Vol. 9:967-972	_

Examiner	702 41	Date	7-71-07
Signature		Considered	()/ /

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

 $[\]scriptstyle\rm I$ Unique citation designation number. $\scriptstyle\rm 2$ Applicant is to place a check mark here if English language Translation is attached.

FEB 2 5 2002 301

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 4 of 4

o a collection of information unless it displays a valid OMB control number.			
Application Number	09/875,456	<u> </u>	
Filing Date	June 6, 2001		
First Named Inventor	Qin, et. al.	- E	
Group Art Unit	1615	=	
Examiner Name		8	
Attorney Docket Number	ORT-1448	0/29	

		OTHER REION ART. MON PATENT LITERATURE POCUMENTS	
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner 's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	37	WALLACE, R. H., et al., "Febrile Seizures And Generalized Epilepsy Associated With A Mutation In The Na+Channel β1 Subunit Gene Scn1b," Nature Genetics 19 (1998) 366-370	-
V	38	WAXMAN, STEPHEN, et al., "Conductin Through Demyelinated Plaques In Multiple Sclerosis; Computer Simulations Of Facilitation By Short Internodes," Journal of Neurology, Neurosurgery, and Psychiatry 41 (1978) 408-416	
	39	WAXMAN, S.G., et al., "Sodium Channels And Pain, "Proc. Natl. Acad. Sci, USA, 1999 Vol 96, 7635-7639	/
	40	WAXMAN SG, et al. "Type III Sodium Channel mRNA Is Expressed In Embryonic But Not Adult Spinal Sensory Neurons, And Is Reexpressed Following Axotomy," J Neurophysiol 72:466-470(1994)	~
~	41	YAMAMOTO, YOSHIO et al., "Important Role Of The Proline Residue In The Signal Sequence That Directs The Secretion Of Human Lysozyme In Saccharomyces Cerevisiae," Biochemistry (1989), 28:2728-2732	
2	42	DEVEREUX, J. et al., "A Comprehensive Set Of Sequence Analysis Programs For The Vax", Nucleic Acids Research, (1984) Vol. 12:387-395,	_
~	43	ISOM & CATTERALL, "Na+ Channel Subunits And Ig Domains," Nature (1996) Vol. 383:307-308	
2	44	KAUFMAN, R.J., et al., "Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene," J. Mol. Biol. (1982) Vol. 159:601-621	_
~	45	TAGLIALATELA, M., et al., "Novel Voltage Clamp To Record Small, Fast Currents From Ion Channels Epressed In Xenopus Oocytes," Biophys. J. (1992) Vol. 61:78-82	-
	46	WIGLER, M., et al., "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells," Cell (1977) Vol. 11:223-232	-
	47	KAZEN-GILLESPIE, K. A. et al., "Cloning, Localization, and Functional Expression of Sodium Channel β1A Subunits", Journal of Biological Chemistry (2000) Vol. 275:1079-1088	
-	48	KIM, SUN HO and CHUNG, JIN MO, "An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat" Pain 50 (1992) 355-363	/
-			

		<u> </u>			
Examiner I	τ_{i}	n -	Date	9 27 -()	
Cianatura	104		l	7-(/-0)	I I
Signature			Considered	<i>) </i>	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

#AD A 8 2002

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.